Mount Sinai Health System Launches i3 Prism, a Technology Commercialization Fund focused on Female and BIPOC Inventors
i3 Prism aims to bring new health care solutions to patients and society by advancing technologies from women and BIPOC inventors closer to the marketplace. Mount Sinai Innovation Partners (MSIP), the commercialization arm of the Mount Sinai Health System in New York, …
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
Sema4 (NASDAQ: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY recently published a study in Nature Communications using network modeling to identify novel …
Clinical Research Associates GRITT™ Resilience-based Methodology with Significantly Reduced Healthcare Utilization and Opioid Use in Patients with IBD
Research published in Clinical Gastroenterology and Hepatology following 394 IBD patients found significantly improved outcomes with use of GRITT™ methodology, augmenting previous findings Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, resilience-based, connected health solution for chronic condition management, …
PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders to Commercialize Cancer Risk Stratification Services to Support Better Patient Insights and Outcomes
Services Improve the Information Available to Oncologists and Pathologists in Determining Patient Risk Profiles and Treatment Diagnostic Industry Veteran Wayne Brinster Joins as CEO PreciseDx, the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, …
MSIP Honors SARS-CoV-2 and Drug Discovery Research Teams at Innovation Awards Ceremony
At the annual Innovation Awards Ceremony on November 8, Mount Sinai Innovation Partners (MSIP) presented the Inventor of the Year, Transaction of the Year, and Mount Sinai Pitch Challenge awards to Mount Sinai innovators who are developing impactful, patient-centered solutions. The Inventor …
Linus Biotechnology Inc. Receives FDA Breakthrough Device Designation for StrandDx™-ASD Exposome Sequencing Diagnostic
Linus Biotechnology Inc., a leader in precision exposome sequencing, today announced that the U.S. Food and Drug Administration Center for Devices and Radiological Health has granted the Company’s StrandDx™-ASD diagnostic aid the designation as a Breakthrough Device for Autism Spectrum Disorder (ASD). …
Linus Biotechnology Inc. Receives FDA Breakthrough Device Designation for StrandDx™-ASD Exposome Sequencing Diagnostic
Linus Biotechnology Inc., a leader in precision exposome sequencing, today announced that the U.S. Food and Drug Administration Center for Devices and Radiological Health has granted the Company’s StrandDx™-ASD diagnostic aid the designation as a Breakthrough Device for Autism Spectrum Disorder (ASD). …
Mount Sinai Spin-Off Linus Biotechnology Inc. to Revolutionize Precision Medicine with Exposome Sequencing
Linus Biotechnology Inc. and Mount Sinai Innovation Partners (MSIP) today announced an exclusive worldwide license and collaboration agreement in progress with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), the medical school of the Mount Sinai Health System (Mount …
Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction
Sema4, an AI-driven genomic and clinical data intelligence platform company, recently published two studies demonstrating the utility of machine learning to predict clinical outcomes for postpartum hemorrhage (PPH). The studies, which will appear in a special “Informatics for Sex- and Gender-Related Health” …
BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced two new academic collaborations with Columbia University and Mount Sinai (Icahn Mount Sinai) to translate cutting-edge research discoveries into potential therapies for patients with genetic diseases and genetically driven cancers. “Columbia …